$13.06 -$0.08 (-0.6%)

04:00 PM EST on 01/24/20

Corcept Therapeutics, Inc. (NASDAQ:CORT)

CAPS Rating: 3 out of 5

A pharmaceutical company which is engaged in the development of drugs for the treatment of severe psychiatric and metabolic diseases.

Current Price $13.06 Mkt Cap $1.5B
Open $13.13 P/E Ratio 17.33
Prev. Close $13.13 Div. (Yield) $0.00 (0.0%)
Daily Range $13.01 - $13.35 Volume 760,768
52-Wk Range $11.62 - $13.35 Avg. Daily Vol. 830,431


How do you think NASDAQ:CORT will perform against the market?

Add Stock to CAPS Watchlist

All Players

81 Outperform
26 Underperform

All-Star Players

10 Outperform
5 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:CORT Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

vistacarolina (32.12)
Submitted March 31, 2017

Great Co. will see positive results.

zzlangerhans (99.62)
Submitted July 13, 2016

In medicine we generalists have a saying: When you only tool is a hammer, every problem becomes a nail. It refers to the propensity of specialists to interpret every problem through the lens of their specialty. If a patient comes in with syncope, the… More

Recent Community Commentary

Read the most recent pitches from players about CORT.


Member Avatar MarkBiotech (< 20) Submitted: 3/7/2018 6:03:49 PM : Outperform Start Price: $15.75 NASDAQ:CORT Score: -37.62

Corcepts lead product korlym is expected to lose exclusivity in 2019.. although that seems concerning.. it isnt.. the small market size in CS will prevent price wars for when generics do enter into the market.. also, Relacorilant, an improved product for CS will EASILY replace Korlym.. Relacorilant will make korlym and any other generic competitors in the space absolete.. Relacorilant is also being explored in clinical trials in combination with abraxane for solid tumors.. Management has expressed that early results have been promising.. If solid tumor data results are as good as managements optimism, we can see CORT fly well above what it is currently worth.. Management are also exploring other combo therapies including korlym in TNBC, CORT125281+xtandi in CRPC.. Also CORT118335 for NASH shouldn't be taken out of the picture.. since their pipeline are all in early stages of development, CORT is considered a speculative play in the favor of longs. the preliminary data of Relacorilant is robust(despite low N) and was executed with the low-end dose.. a higher dose should prove to have better efficacy... Abraxane as a stand alone agent for solid tumors has shown to work in LC,TNBC, CRPC.. the problem with early clinical combo therapies(W/O single agent data), is that sometimes it is hard to figure out whether the net effect is from the combo or from the standalone agent. regardless this confusion of benefit from the combo should boost CORT's share price as market investors are incompetent of realizing the difference between solo efficacy vs combo efficacy.. (see nktr-214).


Member Avatar aeroberts831 (< 20) Submitted: 3/5/2018 9:18:29 PM : Outperform Start Price: $14.68 NASDAQ:CORT Score: -31.61

Teva ANDA announcement of Corcept's lead product Korlym tanked stock 40%, but Teva will not bring to market a generic formulation of Korlym with any meaningful effect on Corcept's revenues.


Member Avatar zzlangerhans (99.62) Submitted: 7/13/2016 9:38:18 AM : Underperform Start Price: $5.52 NASDAQ:CORT Score: -79.15

In medicine we generalists have a saying: When you only tool is a hammer, every problem becomes a nail. It refers to the propensity of specialists to interpret every problem through the lens of their specialty. If a patient comes in with syncope, the cardiologist wants to order an ECHO and the neurologist wants an MRI. In the case of Corcept, their only tool is mifepristone and they generate pipeline by finding new diseases to apply their tool against. The Cushing's syndrome indication likely won't be enough to turn Corcept cash-flow positive, so the company has turned its attention to cancers, specifically TNBC and CRPC. There's some independent evidence that this may be an effective strategy, but not much. As of now I think Corcept is overvalued at a cap of 600M for Korlym's weak revenues and risky prospects as a cancer drug.


Find the members with the highest scoring picks in CORT.

Score Leader


thiscoloradokid (< 20) Score: +627.76

The Score Leader is the player with the highest score across all their picks in CORT.

Member Name Member
Call Time
Score Commentary
thiscoloradokid < 20 12/5/2012 12/4/2013 Outperform 3M $1.52 +760.20% +132.44% +627.76 0 Comment
alvojiggy 78.21 10/23/2013 Outperform 5Y $1.73 +655.78% +87.98% +567.80 0 Comment
GOGCwatch07 < 20 9/18/2013 Outperform 5Y $1.73 +655.78% +92.15% +563.63 0 Comment
FinanceGuy58 55.26 12/9/2013 7/24/2015 Outperform 3Y $2.01 +552.12% +81.29% +470.83 0 Comment
wgrohman < 20 3/21/2013 Outperform 3Y $1.94 +573.97% +112.33% +461.64 0 Comment
HoosierDoozer < 20 12/5/2013 Outperform 5Y $2.06 +534.71% +83.16% +451.55 0 Comment
loangolfer < 20 1/10/2013 11/14/2019 Outperform NS $1.96 +566.75% +124.09% +442.67 0 Comment
HoldThatWinner 29.26 3/11/2013 Outperform 1Y $2.00 +553.75% +111.56% +442.19 0 Comment
cavemantrader 26.37 11/29/2013 Outperform 5Y $2.10 +522.62% +81.23% +441.39 1 Comment
rserafini 76.83 3/25/2013 Outperform 5Y $2.04 +540.93% +110.63% +430.30 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for CORT.